Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)

6 Months Ended

Jul. 02, 2023

Schedule of Basic and Diluted Earning Per Share


The following presents the detailed calculation of EPS:
	Three Months Ended				Six Months Ended
(MILLIONS)	July 2, 2023		July 3, 2022		July 2, 2023		July 3, 2022
EPS Numerator––Basic


Income from continuing operations attributable to Pfizer Inc. common shareholders	$	2,329	$	9,871	$	7,871	$	17,743
Discontinued operations––net of tax	(2)		34		(1)		26


Net income attributable to Pfizer Inc. common shareholders	$	2,327	$	9,906	$	7,870	$	17,769
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	2,329	$	9,871	$	7,871	$	17,743
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	(2)		34		(1)		26
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	2,327	$	9,906	$	7,870	$	17,769
EPS Denominator
Weighted-average number of common shares outstanding––Basic	5,646		5,593		5,640		5,605
Common-share equivalents	67		119		80		130
Weighted-average number of common shares outstanding––Diluted	5,713		5,712		5,720		5,735
Anti-dilutive common stock equivalents(a)	3		1		2		—

(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.